MedTrace Logo

A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer

NCT06612151 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 438

Last updated 2025-02-11

No results posted yet for this study

Summary

This study was designed to compare the efficacy and safety of YL201 with Topotecan Hydrochloride in subjects with relapsed small cell lung cancer (SCLC).

Conditions

Interventions

DRUG

YL201

Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks (Q3W) as a cycle at RP3D dose level.

DRUG

topotecan hydrochloride for injection

Topotecan hydrochloride will be administered intravenously per prescribing information.

Sponsors & Collaborators

  • MediLink Therapeutics (Suzhou) Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-17
Primary Completion
2027-12-01
Completion
2030-12-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06612151 on ClinicalTrials.gov